Tools
Tools
Fokkens, Wytske J., Mullol, Joaquim, Kennedy, David, Philpott, Carl 
ORCID: https://orcid.org/0000-0002-1125-3236, Seccia, Veronica, Kern, Robert C., Coste, André, Sousa, Ana R., Howarth, Peter H., Benson, Victoria S., Mayer, Bhabita, Yancey, Steve W., Chan, Robert and Gane, Simon B.
(2023)
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis.
Allergy, 78 (3).
pp. 812-821.
ISSN 0105-4538
Preview |
PDF (Allergy - 2022 - Fokkens - Mepolizumab for chronic rhinosinusitis with nasal polyps SYNAPSE in‐depth sinus surgery)
- Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
Abstract
Background: Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often require repeat sinus surgery. Mepolizumab reduced the need for sinus surgery in the SYNAPSE trial; this analysis sought to provide a more in-depth assessment of surgery endpoints in SYNAPSE. Methods: SYNAPSE was a double-blind Phase III trial (NCT03085797) in adults with recurrent, refractory, severe, CRSwNP eligible for repeat sinus surgery despite standard of care treatments and previous surgery. Patients were randomized (1:1) to mepolizumab 100 mg subcutaneously or placebo, plus standard of care, every 4 weeks for 52 weeks. Time to first inclusion on a waiting list for sinus surgery and time to first actual sinus surgery (both up to week 52) were assessed; the latter endpoint was also analyzed post hoc according to time since last sinus surgery before study screening and baseline blood eosinophil count. Results: Among 407 patients (mepolizumab: 206; placebo: 201), mepolizumab versus placebo reduced the risk of being included on a waiting list for sinus surgery (week 52 Kaplan–Meier probability estimate [95% confidence interval]: 13.9% [9.8%, 19.5%] vs. 28.5% [22.7%, 35.4%]). Mepolizumab versus placebo reduced the risk of sinus surgery irrespective of time (<3 vs ≥3 years) since patients' last sinus surgery prior to study screening (hazard ratios [95% confidence intervals] 0.28 [0.09, 0.84] and 0.50 [0.26, 0.98], respectively) and baseline blood eosinophil count. Conclusions: Mepolizumab reduced the risk of further sinus surgery in patients with recurrent, refractory, severe CRSwNP, irrespective of the patient baseline characteristics assessed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | chronic rhinosinusitis with nasal polyps,mepolizumab,recurrence,refractory,sinonasal surgery,immunology and allergy,immunology ,/dk/atira/pure/subjectarea/asjc/2700/2723 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 25 Jul 2022 08:30 |
| Last Modified: | 19 Oct 2023 03:23 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/86835 |
| DOI: | 10.1111/all.15434 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |